Neurogenic Bladder



The term “neurogenic bladder” encompasses a variety of clinical and urodynamic entities. In general, it refers to clinical problems related to bladder dysfunction secondary to underlying neurological conditions. It is important to obtain a thorough clinical history followed by examination including a good neurological assessment. While this may give clues to the underlying problem, correct management will not be achieved without the aid of laboratory testing, imaging, and urodynamic evaluation, the last in many patients playing a key role in their management. While certain conditions may warrant specific treatments, management, in general, becomes easy once patients are classified based on their urodynamic pattern. The key determinant in the management of neuro-urological problems is to ascertain whether the bladder is “safe” or “unsafe,” i.e., its impact on the renal function. Once this has been determined, management of these entities becomes easy. It is worth remembering that the bladder is a dynamic organ and tends to change physiologically and hence functionally over time. In this chapter, key concepts in identification and management of common clinical entities that cause “neurogenic bladder” will be discussed.


Stress Urinary Incontinence Botulinum Toxin Pelvic Organ Prolapse Neurogenic Bladder Urethral Sphincter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



I am grateful to Prof. Chris Chapple, Consultant Urological Surgeon, Sheffield Teaching Hospitals, and Honorary Professor, Sheffield Hallam University, UK, for his review of the manuscript.


  1. 1.
    Rortveit G, Hannestad YS, Daltveit AK, Hunskaar S. Age- and type-dependent effects of parity on urinary incontinence: the Norwegian EPINCONT study. Obstet Gynecol. 2001;98:1004–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia. 1990;28:217–29.PubMedCrossRefGoogle Scholar
  3. 3.
    Haylen B, Ridder D, Freeman R, Steven S, Berghmans B, et al. An International Urogynaecological Association (IUGA), International Continence Society (ICS) joint report on the terminology of pelvic floor dysfunction. NeurourolUrodyn. 2010;29:4–20.Google Scholar
  4. 4.
    Furlan JC. Autonomic dysreflexia: a clinical emergency. JTrauma Acute Care Surg. 2013;75:496–500.CrossRefGoogle Scholar
  5. 5.
    McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126:205–9.PubMedGoogle Scholar
  6. 6.
    McGuire EJ, Fitzpatrick CC, Wan J, Bloom D, Sanvordenker J, Ritchey M, Gormley EA. Clinical assessment of urethral sphincter function. J Urol. 1993;150:1452–4.PubMedGoogle Scholar
  7. 7.
    Madersbacher H, Mürtz G, Stöhrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51:432–41.PubMedCrossRefGoogle Scholar
  8. 8.
    Radomski S, Jayarajan J. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol. 2014;6:1–16.PubMedCentralGoogle Scholar
  9. 9.
    Kakizaki H, Ameda K, Kobayashi S, Tanaka H, Shibata T, Koyanagi T. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. Int J Urol. 2003;10(11):576–81.PubMedCrossRefGoogle Scholar
  10. 10.
    Cameron A, Clemens J, Latini J, McGuire E. Combination drug therapy improves compliance of the neurogenic bladder. J Urol. 2009;182:1062–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Mangera A, Andersson K-EE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, Gravas S, Madersbacher S. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60:784–95.PubMedCrossRefGoogle Scholar
  13. 13.
    Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, Yoshimura N, Chancellor MB. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol. 2001;165(4):1107–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Chartier-Kastler E, Denys P. Intermittent catheterization with hydrophilic catheters as a treatment of chronic neurogenic urinary retention. NeurourolUrodyn. 2011;30:21–31.Google Scholar
  15. 15.
    Wein AJ. Lower urinary tract dysfunction in neurologic injury and disease. In: Wein AJ et al., editors. Campbell-Walsh urology. 9th ed. Philadelphia: Saunders; 2007.Google Scholar
  16. 16.
    Osman N, Chapple C. Fowler’s syndrome – a cause of unexplained urinary retention in young women? Nat Rev Urol. 2014;11:87–98.PubMedCrossRefGoogle Scholar
  17. 17.
    Seth JH, Sahai A, Khan MS, Van der AF, de Ridder D, Panicker JN, Dasgupta P, Fowler CJ. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)? BJU Int. 2013;111:372–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Peters K, Gilmer H, Feber K, Girdler B, Nantau W, Trock G, Killinger K, Boura J. US pilot study of lumbar to sacral nerve rerouting to restore voiding and bowel function in spina bifida: 3-year experience. Adv Urol. 2014;17 Article ID 863209, 7 pages. doi: 10.1155/2014/863209.

Copyright information

© Springer India 2015

Authors and Affiliations

  1. 1.Department of UrologyCanadian Specialist HospitalDubaiUAE

Personalised recommendations